2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2013
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy